查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1886902

氘代丁苯那嗪市場規模、佔有率、成長及全球產業分析：依類型、應用和地區劃分的洞察，以及2024-2032年預測

Deutetrabenazine Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 150 Pages | 商品交期: 請詢問到貨日

價格

氘代丁苯那嗪市場成長驅動因子

受神經系統疾病診斷率上升和監管審批範圍擴大的推動，全球氘代丁苯那嗪市場保持強勁成長勢頭。 2024年，該市場價值16.9億美元，預計2025年將成長至20.3億美元，到2032年將達到54.2億美元。 2025年至2032年間強勁的複合年增長率（15.1%）反映了應用領域的不斷拓展、疾病認知度的提高以及已獲批准的VMAT2抑制劑的出色表現。

北美市場佔絕對主導地位，2024年佔全球市佔率的94.08%。這得歸功於亨丁頓舞蹈症（HD）和遲發性運動障礙（TD）的高發生率、完善的醫療保健基礎設施、持續的宣傳活動以及早期的監管審批。氘代丁苯那嗪主要由梯瓦製藥工業有限公司以 "AUSTEDO" 品牌銷售，目前仍處於專利保護期，這限制了仿製藥的競爭，並鞏固了梯瓦的市場主導地位。

市場動態

市場推動因素

神經退化性疾病（尤其是亨丁頓舞蹈症和遲發性運動障礙）發生率的持續上升是氘代丁苯那嗪應用的主要推動因素。基因檢測的普及、臨床意識的提高以及早期診斷的普及使得及時治療介入成為可能。例如，根據罕見疾病諮詢機構2023年的報告，預計北美亨廷頓舞蹈症的盛行率將達到每10萬人8.87例，這凸顯了需要長期VMAT2抑制劑治療的患者群體不斷擴大。

不斷增加的研發投入以及製藥業對新製劑開發的重視進一步推動了市場擴張。各大醫療機構在治療指引中擴大採用氘代丁苯那嗪也促進了其廣泛應用。

市場限制因子

儘管應用日益廣泛，但生產流程的複雜性正在影響市場成長。氘代過程會減緩藥物代謝並提高療效，但同時也會增加生產成本，使新興市場難以負擔。長期安全性問題也可能阻礙藥物的持續治療應用。

監管壁壘，包括歐洲藥品管理局 (EMA) 和美國食品藥物管理局 (FDA) 嚴格的上市後監測要求，延長了新適應症和新劑型的審批流程，延緩了藥物的廣泛商業化。

市場機會

緩釋 (XR) 製劑代表著一個重要的機會。梯瓦製藥的 AUSTEDO XR（將於 2024 年 5 月上市）採用每日一次給藥的便利方式，有助於提高患者依從性並增加處方量。製藥公司也正在利用生命週期管理策略，包括開發新的劑量規格、拓展地域範圍以及針對更多神經系統疾病進行擴大的臨床試驗。

亞太地區，尤其是中國、韓國和印度，由於診斷率的提高和醫療服務可近性的改善，成長潛力依然巨大。 2020年5月，中國國家藥品監督管理局（NMPA）批准AUSTEDO上市，顯著加速了該地區的擴張。

市場挑戰

來自其他VMAT2抑制劑（例如丁苯那嗪（Xenazine）和纈苯那嗪（Ingrezza））的競爭持續給市場帶來壓力。這些藥物的給藥方案和副作用各不相同，影響著處方醫師的選擇和價格競爭。

市場趨勢

地域擴張是一個顯著的趨勢。各公司正在歐洲、亞太和拉丁美洲尋求批准和商業合作。策略性專利申請持續保護市場獨佔權，預計2030年之前不會出現仿製藥競爭。

擴大患者權益倡導工作，特別是提高顳顎關節運動障礙（TD）的認知度，也有助於改善診斷和治療的普及。此外，對更廣泛的神經系統疾病適應症（例如妥瑞氏症）的臨床投資，預示著未來的成長機會。

市場區隔分析

依應用領域

  • 由於遲發性運動障礙（TD）的高發病率和不斷提高的認知度，預計到2024年，TD將佔最大的市場佔有率。美國的 "TD宣傳週" 也印證了這個趨勢。
  • 由於研發投入的增加以及透過基因檢測進行早期診斷的進步，亨廷頓氏症（HD）的市場佔有率預計將快速增長。

依通路劃分

  • 由於氘代丁苯那嗪屬於處方藥，預計到2024年，醫院藥局將佔分銷管道的大部分佔有率。
  • 隨著提供神經專科治療的藥局數量增加，零售藥局和藥局的市佔率預計將會擴大。

區域亮點

北美（2024年：15.9億美元）

由於早期應用、疾病高發、研發投入巨大以及梯瓦製藥的強大影響力，該地區在全球佔領先地位。在美國，市場需求持續受到宣傳活動和先進神經科中心的推動。

歐洲

公共醫療保健支出增加、歐洲藥品管理局 (EMA) 的批准以及亨廷頓​​病 (HD) 患病率上升（2023 年每 10 萬人中有 6.37 人患病）正在推動該地區的穩步增長。

亞太地區

監管審批的增加、診斷技術的改進以及神經病學護理基礎設施的擴展預計將推動該地區的顯著增長。

其他地區

由於疾病認知度低和神經病學基礎設施不足，成長仍較為溫和。

目錄

第一章：引言

第二章：摘要整理

第三章：市場動態

  • 市場推動因素
  • 市場阻礙因素
  • 市場機遇
  • 市場趨勢

第四章：主要發現

  • 主要疾病的流行病學
  • 主要國家的監管狀況
  • 主要國家的報銷狀況
  • 主要公司的研產品線分析
  • 主要產業趨勢（併購、合作等）
  • 主要公司的新產品發布

第五章：全球氘代丁苯那嗪市場分析、洞察與預測（2019-2032）

  • 市場分析、洞察與預測 - 依應用領域劃分
    • 亨丁頓舞蹈症
    • 遲發性運動障礙
    • 其他
  • 市場分析、洞察與預測 - 依分銷管道劃分
    • 醫院藥房
    • 零售藥局和藥局
    • 線上藥房
  • 市場分析、洞察與預測 - 依地區劃分
    • 北美
    • 歐洲
    • 亞太地區
    • 其他

第六章 北美氘代激動劑市場分析、洞察與預測（2019-2032）

  • 依國家/地區
    • 美國
    • 加拿大

第七章：歐洲氘代烷市場分析、洞察與預測（2019-2032）

  • 依國家劃分
    • 德國
    • 法國
    • 西班牙
    • 義大利
    • 歐洲其他地區

第八章：亞太地區氘代烷市場分析、洞察與預測（2019-2032）

  • 依國家劃分
    • 日本
    • 中國
    • 印度
    • 澳大利亞
    • 亞太其他地區

第九章：其他氘代烷市場分析、洞察與預測（2019-2032）

第十章：競爭分析

  • 全球市佔率分析（2024）
  • 公司簡介
    • 梯瓦製藥工業股份有限公司
    • 其他主要參與者
Product Code: FBI113542

Growth Factors of deutetrabenazine Market

The global deutetrabenazine market continues strong upward momentum, driven by rising diagnosis of neurological disorders and broader regulatory approvals. Valued at USD 1.69 billion in 2024, the market is projected to grow to USD 2.03 billion in 2025 and further reach USD 5.42 billion by 2032. A robust CAGR of 15.1% during 2025-2032 reflects expanding applications, increasing disease awareness, and the strong performance of approved VMAT2 inhibitors.

The market is significantly dominated by North America, which accounted for 94.08% of global share in 2024, supported by a high prevalence of Huntington's disease (HD) and tardive dyskinesia (TD), strong healthcare infrastructure, ongoing awareness programs, and early regulatory approvals. Deutetrabenazine, primarily commercialized under the brand name AUSTEDO by Teva Pharmaceutical Industries Ltd., remains patent-protected, limiting generic competition and strengthening Teva's market dominance.

Market Dynamics

Market Growth Drivers

Rising cases of neurodegenerative disorders-especially HD and TD-remain the strongest driver for deutetrabenazine adoption. Greater access to genetic testing, improved clinical awareness, and early diagnosis enable timely therapeutic intervention. For instance, the Rare Disease Advisory reported in 2023 that HD prevalence in North America reached 8.87 per 100,000 population, highlighting the growing patient pool requiring long-term VMAT2 inhibitor therapy.

Increasing research investments and pharmaceutical focus on new formulations further support market expansion. Broader acceptance of deutetrabenazine in treatment guidelines across major healthcare systems is also fueling uptake.

Market Restraints

Despite rising adoption, market growth is affected by manufacturing complexities. The deuteration process, which slows drug metabolism and enhances efficacy, also increases production costs-reducing affordability in emerging markets. Long-term safety concerns may also hinder sustained therapy use.

Regulatory hurdles, including rigorous EMA and FDA post-marketing surveillance requirements, extend approval timelines for new indications and formulations, delaying broader commercialization.

Market Opportunities

A major opportunity lies in extended-release (XR) formulations. Teva's AUSTEDO XR, launched in May 2024, introduced once-daily dosing convenience, improving patient adherence and supporting prescription growth. Pharmaceutical companies are also leveraging lifecycle management strategies, including new dosing strengths, geographic expansion, and broader clinical trials targeting additional neurological disorders.

Growth potential in Asia Pacific, particularly in China, South Korea, and India, remains strong due to rising diagnosis rates and increasing accessibility. China's NMPA approval of AUSTEDO in May 2020 significantly opened the region for expansion.

Market Challenges

Competition from alternative VMAT2 inhibitors such as tetrabenazine (Xenazine) and valbenazine (Ingrezza) presents ongoing market pressure. These drugs offer different dosing regimens and side-effect profiles, influencing prescriber preference and pricing competition.

Market Trends

A prominent trend is geographical expansion, with companies pushing for approvals and commercial partnerships across Europe, Asia Pacific, and Latin America. Strategic patent filings continue to protect market exclusivity, with generic competition unlikely before 2030.

Growing patient advocacy campaigns-especially regarding TD awareness-are also improving diagnosis and boosting treatment adoption. Additionally, clinical investments targeting broader neurological indications like Tourette syndrome present future growth opportunities.

Segmentation Analysis

By Application

  • Tardive Dyskinesia (TD) held the largest share in 2024 due to high prevalence and growing awareness. TD Awareness Week in the U.S. underscores this trend.
  • Huntington's Disease (HD) is expected to grow rapidly due to rising R&D efforts and earlier diagnosis through genetic testing.

By Distribution Channel

  • Hospital pharmacies dominated in 2024 given the prescription-only status of deutetrabenazine.
  • Retail pharmacies & drug stores are expected to expand as more pharmacies stock specialty neurological drugs.

Regional Highlights

North America (USD 1.59 billion in 2024)

The region leads globally due to early adoption, high disease prevalence, substantial R&D spending, and strong presence of Teva Pharmaceuticals. The U.S. continues to drive market demand supported by awareness programs and advanced neurology centers.

Europe

Rising public healthcare spending, EMA approvals, and growing prevalence of HD (6.37 per 100,000 individuals in 2023) contribute to the region's steady expansion.

Asia Pacific

The region is poised for significant growth due to increasing regulatory approvals, better diagnostics, and expanding neurological care infrastructure.

Rest of World

Growth remains modest due to lower disease awareness and limited neurology infrastructure.

Conclusion

The deutetrabenazine market's rise-from USD 1.69 billion in 2024 to a projected USD 5.42 billion by 2032-shows strong momentum fueled by increasing diagnosis of neurodegenerative disorders, introduction of XR formulations, and robust expansion efforts by Teva. Continued regulatory approvals and clinical innovations will remain central to future market growth.

Segmentation By Application

  • Huntington's Disease
  • Tardive Dyskinesia
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies & Drug Stores
  • Online Pharmacies

By Region

  • North America (By Application, Distribution Channel, and Country)
    • U.S.
    • Canada
  • Europe (By Application, Distribution Channel, and Country/Sub-region)
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific (By Application, Distribution Channel, and Country/Sub-region)
    • China
    • Japan
    • India
    • Australia
    • Rest of Asia Pacific
  • Rest of the World (By Application and Distribution Channel)

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Epidemiology of Key Diseases
  • 4.2. Regolatory Scenario, By Key Countries/Regions
  • 4.3. Reimbursement Scenario, By Key Countries/Regions
  • 4.4. Pipeline Analysis, By Key Players
  • 4.5. Key Industry Developments (Mergers, Acquisitions, and Collaborations etc.)
  • 4.6. New Product Launches, By Key Players

5. Global Deutetrabenazine Market Analysis, Insights and Forecast, 2019-2032

  • 5.1. Market Analysis, Insights and Forecast - By Application
    • 5.1.1. Huntington's Disease
    • 5.1.2. Tardive Dyskinesia
    • 5.1.3. Others
  • 5.2. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.2.1. Hospital Pharmacies
    • 5.2.2. Retail Pharmacies & Drug Stores
    • 5.2.3. Online Pharmacies
  • 5.3. Market Analysis, Insights and Forecast - By Region
    • 5.3.1. North America
    • 5.3.2. Europe
    • 5.3.3. Asia Pacific
    • 5.3.4. Rest of the World

6. North America Deutetrabenazine Market Analysis, Insights and Forecast, 2019-2032

  • 6.1. Market Analysis, Insights and Forecast - By Application
    • 6.1.1. Huntington's Disease
    • 6.1.2. Tardive Dyskinesia
    • 6.1.3. Others
  • 6.2. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.2.1. Hospital Pharmacies
    • 6.2.2. Retail Pharmacies & Drug Stores
    • 6.2.3. Online Pharmacies
  • 6.3. Market Analysis, Insights and Forecast - By Country
    • 6.3.1. U.S.
    • 6.3.2. Canada

7. Europe Deutetrabenazine Market Analysis, Insights and Forecast, 2019-2032

  • 7.1. Market Analysis, Insights and Forecast - By Application
    • 7.1.1. Huntington's Disease
    • 7.1.2. Tardive Dyskinesia
    • 7.1.3. Others
  • 7.2. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.2.1. Hospital Pharmacies
    • 7.2.2. Retail Pharmacies & Drug Stores
    • 7.2.3. Online Pharmacies
  • 7.3. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 7.3.1. K.
    • 7.3.2. Germany
    • 7.3.3. France
    • 7.3.4. Spain
    • 7.3.5. Italy
    • 7.3.6. Rest of Europe

8. Asia Pacific Deutetrabenazine Market Analysis, Insights and Forecast, 2019-2032

  • 8.1. Market Analysis, Insights and Forecast - By Application
    • 8.1.1. Huntington's Disease
    • 8.1.2. Tardive Dyskinesia
    • 8.1.3. Others
  • 8.2. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.2.1. Hospital Pharmacies
    • 8.2.2. Retail Pharmacies & Drug Stores
    • 8.2.3. Online Pharmacies
  • 8.3. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 8.3.1. Japan
    • 8.3.2. China
    • 8.3.3. India
    • 8.3.4. Australia
    • 8.3.5. Rest of Asia Pacific

9. Rest of the World Deutetrabenazine Market Analysis, Insights and Forecast, 2019-2032

  • 9.1. Market Analysis, Insights and Forecast - By Application
    • 9.1.1. Huntington's Disease
    • 9.1.2. Tardive Dyskinesia
    • 9.1.3. Others
  • 9.2. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.2.1. Hospital Pharmacies
    • 9.2.2. Retail Pharmacies & Drug Stores
    • 9.2.3. Online Pharmacies

10. Competitive Analysis

  • 10.1. Global Market Share Analysis (2024)
  • 10.2. Company Profiles
    • 10.2.1. Teva Pharmaceutical Industries Ltd.
      • 10.2.1.1. Overview
      • 10.2.1.2. Products & services
      • 10.2.1.3. SWOT Analysis
      • 10.2.1.4. Recent Developments
      • 10.2.1.5. Strategies
      • 10.2.1.6. Financials (Based on Availability)
    • 10.2.2. Other Prominent Players
      • 10.2.2.1. Overview
      • 10.2.2.2. Products & services
      • 10.2.2.3. SWOT Analysis
      • 10.2.2.4. Recent Developments
      • 10.2.2.5. Strategies
      • 10.2.2.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Deutetrabenazine Market Revenue (USD billion) Forecast, By Application, 2019-2032
  • Table 2: Global Deutetrabenazine Market Revenue (USD billion) Forecast, By Distribution Channel, 2019-2032
  • Table 3: Global Deutetrabenazine Market Revenue (USD billion) Forecast, by Region, 2019-2032
  • Table 4: North America Deutetrabenazine Market Revenue (USD billion) Forecast, By Application, 2019-2032
  • Table 5: North America Deutetrabenazine Market Revenue (USD billion) Forecast, By Distribution Channel, 2019-2032
  • Table 6: North America Deutetrabenazine Market Revenue (USD billion) Forecast, By Country, 2019-2032
  • Table 7: Europe Deutetrabenazine Market Revenue (USD billion) Forecast, By Application, 2019-2032
  • Table 8: Europe Deutetrabenazine Market Revenue (USD billion) Forecast, By Distribution Channel, 2019-2032
  • Table 9: Europe Deutetrabenazine Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 10: Asia Pacific Deutetrabenazine Market Revenue (USD billion) Forecast, By Application, 2019-2032
  • Table 11: Asia Pacific Deutetrabenazine Market Revenue (USD billion) Forecast, By Distribution Channel, 2019-2032
  • Table 12: Asia Pacific Deutetrabenazine Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 13: Rest of the World Deutetrabenazine Market Revenue (USD billion) Forecast, By Application, 2019-2032
  • Table 14: Rest of the World Deutetrabenazine Market Revenue (USD billion) Forecast, By Distribution Channel, 2019-2032

List of Figures

  • Figure 1: Global Deutetrabenazine Market Revenue Breakdown (USD billion, %) by Region, 2024 & 2032
  • Figure 2: Global Deutetrabenazine Market Value Share (%), By Application, 2024 & 2032
  • Figure 3: Global Deutetrabenazine Market Value Share (%), By Distribution Channel, 2024 & 2032
  • Figure 4: Global Deutetrabenazine Market Value (USD billion), by Region, 2024 & 2032
  • Figure 5: North America Deutetrabenazine Market Value (USD billion), By Application, 2024 & 2032
  • Figure 6: North America Deutetrabenazine Market Value Share (%), By Application, 2024
  • Figure 7: North America Deutetrabenazine Market Value (USD billion), By Distribution Channel, 2024 & 2032
  • Figure 8: North America Deutetrabenazine Market Value Share (%), By Distribution Channel, 2024
  • Figure 9: North America Deutetrabenazine Market Value (USD billion), By Country, 2024 & 2032
  • Figure 10: North America Deutetrabenazine Market Value Share (%), By Country, 2024
  • Figure 11: Europe Deutetrabenazine Market Value (USD billion), By Application, 2024 & 2032
  • Figure 12: Europe Deutetrabenazine Market Value Share (%), By Application, 2024
  • Figure 13: Europe Deutetrabenazine Market Value (USD billion), By Distribution Channel, 2024 & 2032
  • Figure 14: Europe Deutetrabenazine Market Value Share (%), By Distribution Channel, 2024
  • Figure 15: Europe Deutetrabenazine Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 16: Europe Deutetrabenazine Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 17: Asia Pacific Deutetrabenazine Market Value (USD billion), By Application, 2024 & 2032
  • Figure 18: Asia Pacific Deutetrabenazine Market Value Share (%), By Application, 2024
  • Figure 19: Asia Pacific Deutetrabenazine Market Value (USD billion), By Distribution Channel, 2024 & 2032
  • Figure 20: Asia Pacific Deutetrabenazine Market Value Share (%), By Distribution Channel, 2024
  • Figure 21: Asia Pacific Deutetrabenazine Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 22: Asia Pacific Deutetrabenazine Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 23: Rest of the World Deutetrabenazine Market Value (USD billion), By Application, 2024 & 2032
  • Figure 24: Rest of the World Deutetrabenazine Market Value Share (%), By Application, 2024
  • Figure 25: Rest of the World Deutetrabenazine Market Value (USD billion), By Distribution Channel, 2024 & 2032
  • Figure 26: Rest of the World Deutetrabenazine Market Value Share (%), By Distribution Channel, 2024
  • Figure 27: Global Deutetrabenazine Market Share (%), By Company, 2024